Dr Reddy'S Launches Generic Bupropion Hydrochloride Extended-Release Tablets In Us

Dr Reddy'S Laboratories On Thursday Said It Has Launched In The Us Generic Bupropion Hydrochloride Extended-Release Tablets Indicated As An Aid To Smoking Cessation Treatment.The Company Has Launched Bupropion Hydrochloride Extended-Release Tablets Usp (Sr), Approved By The United States Food And Drug Administration (Usfda), The Drug Firm Said In A Filing To Bse.The Product Is A Generic Version Of Gsk Group Of Companies' Zyban Extended-Release Tablets, It Added.According To Iqvia Health, The Zyban Brand And Generic Had Us Sales Of Around Usd 5.4 Million Mat For The 12 Months Ended June 2019, The Company Said.Dr Reddy'S Tablets Are Available As 150 Mg Dosage Strength In Bottle Count Sizes Of 60, It Added.Shares Of Dr Reddy'S Laboratories Were Trading At Rs 2,667.05 Per Scrip On Bse, Up 2.51 Per Cent From The Previous Close.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!